Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Noninvasive Testing for Colorectal Cancer Screening: Where Are We Now?

  • Jaeyoung Chun (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Jie-Hyun Kim (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Young Hoon Youn (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Hyojin Park (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2023.07.20
  • Accepted : 2023.07.28
  • Published : 2023.08.20
Download PDF
⟨ Previous Next ⟩

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers and is the leading cause of cancer-related mortality worldwide. Based on the current screening guidelines by the American Cancer Society and Korean multi-society expert committee, CRC screening is recommended in asymptomatic adults starting at the age of 45 years. Fecal immunochemical test-based screening programs reduce the development of CRC and related mortality in the general population. However, this most popular CRC screening strategy demonstrates a crucial limitation due to modest diagnostic accuracy. Colonoscopy may be considered as an alternative primary method for CRC screening; however, its implementation can still be challenging due to concerns regarding invasiveness, low adherence, cost-effectiveness, and quality assurance. To overcome the limitations of current screening tests, innovative noninvasive tests for CRC screening have been developed with advances in molecular biology, genetics, epigenetics, and microbiomics for detecting CRC, which may enhance the approach to CRC screening and diagnosis in clinical practice in the near future. This review explores the emerging screening methods and discusses their potential for integration into current practice.

Keywords

Acknowledgement

Jaeyoung Chun has received a research grant and honorarium from Genomictree Inc.

References

  1. Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol 2017;23:3632-3642. https://doi.org/10.3748/wjg.v23.i20.3632
  2. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. https://doi.org/10.1056/NEJMoa1311194
  3. Fisher DA, Princic N, Miller-Wilson LA, Wilson K, Fendrick AM, Limburg P. Utilization of a colorectal cancer screening test among individuals with average risk. JAMA Netw Open 2021;4:e2122269. https://doi.org/10.1001/jamanetworkopen.2021.22269
  4. Niedermaier T, Balavarca Y, Brenner H. Stage-specific sensitivity of fecal immunochemical tests for detecting colorectal cancer: systematic review and metaanalysis. Am J Gastroenterol 2020;115:56-69. https://doi. org/10.14309/ajg.0000000000000465
  5. Dickinson BT, Kisiel J, Ahlquist DA, Grady WM. Molecular markers for colorectal cancer screening. Gut 2015;64:1485-1494. https://doi.org/10.1136/gutjnl-2014-308075
  6. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-57. https://doi.org/10.1016/s0046-8177(00)80198-7
  7. Fatemi N, Tierling S, Es HA, et al. DNA methylation biomarkers in colorectal cancer: clinical applications for precision medicine. Int J Cancer 2022;151:2068-2081. https://doi.org/10.1002/ijc.34186
  8. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol 2021;116:458-479. https://doi.org/10.14309/ajg.0000000000001122
  9. Naber SK, Knudsen AB, Zauber AG, et al. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS One 2019;14:e0220234. https://doi.org/10.1371/journal.pone.0220234
  10. Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology 2016;151:427-439.e6. https://doi.org/10.1053/j.gastro.2016.06.003
  11. Cotter TG, Burger KN, Devens ME, et al. Long-term follow-up of patients having false-positive multitarget stool DNA tests after negative screening colonoscopy: the LONG-HAUL cohort study. Cancer Epidemiol Biomarkers Prev 2017;26:614-621. https://doi.org/10.1158/1055-9965.EPI-16-0800
  12. Oh TJ, Oh HI, Seo YY, et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 2017;9:126. https://doi.org/10.1186/s13148-017-0426-3
  13. Han YD, Oh TJ, Chung TH, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics 2019;11:51. https://doi.org/10.1186/s13148-019-0642-0
  14. Yeoh KG, Ho KY, Chiu HM, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut 2011;60:1236-1241. https://doi.org/10.1136/gut.2010.221168
  15. Chiu HM, Ching JY, Wu KC, et al. A risk-scoring system combined with a fecal immunochemical test is effective in screening high-risk subjects for early colonoscopy to detect advanced colorectal neoplasms. Gastroenterology 2016;150:617-625.e3. https://doi.org/10.1053/j.gastro.2015.11.042
  16. Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol 2023;21:604-616. https://doi.org/10.1016/j.cgh.2022.12.008
  17. Bosch LJW, de Wit M, Pham TV, et al. Novel stool-based protein biomarkers for improved colorectal cancer screening: a case-control study. Ann Intern Med 2017;167:855-866. https://doi.org/10.7326/M17-1068
  18. Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 2019;25:679-689. https://doi.org/10.1038/s41591-019-0406-6
  19. Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70-78. https://doi.org/10.1136/gutjnl-2015-309800
  20. Liang JQ, Wong SH, Szeto CH, et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J Gastroenterol Hepatol 2021;36:1035-1043. https://doi.org/10.1111/jgh.15171
  21. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-325. https://doi.org/10.1136/gutjnl-2012-304149
  22. Jin P, Kang Q, Wang X, et al. Performance of a secondgeneration methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 2015;30:830-833. https://doi.org/10.1111/jgh.12855
  23. Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by wholegenome sequencing of plasma cell-free DNA. BMC Cancer 2019;19:832. https://doi.org/10.1186/s12885-019-6003-8
  24. Lee J, Kim HC, Kim ST, et al. Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC). J Clin Oncol 2021;39(15 Suppl):3536. https://doi.org/10.1200/JCO.2021.39.15_suppl.3536